Table 3

Weighted and unweighted sociodemographic characteristics (%) and; patient-reported outcomes (means and percentages) for PiCTure study respondents

		Unweighted %	Weighted %*
Sociodemographic characteristics
Jurisdiction	RoI	70%	77%
	NI	30%	23%
Age at diagnosis (years)	≤59	24%	22%
	60–69	49%	44%
	≥70	24%	34%
Survivorship phase	Short-term	48%	42%
	Long-tem	32%	43%
	Very long-term	20%	16%
Patient-reported outcomes
EQ-5D-5L	Utility score	0.82	0.82
	Mobility	1.6	1.6
	Self-care	1.2	1.2
	Usual activities	1.6	1.7
	Pain/discomfort	1.6	1.6
	Anxiety/depression	1.4	1.4
EORTC QLQ-C30	GHS	71.53	71.15
Functioning subscales	Physical functioning	82.16	81.54
	Role functioning	80.91	80.57
	Emotional functioning	83.51	83.66
	Cognitive functioning	82.27	82.24
	Social functioning	82.16	82.48
Symptoms subscales	Fatigue	23.96	23.92
	Nausea and vomiting	4.19	4.06
	Pain	15.39	15.20
	Dyspnoea	16.87	16.82
	Insomnia	23.57	23.29
	Appetite loss	7.00	7.00
	Constipation	13.16	13.37
	Diarrhoea	9.69	9.57
	Financial difficulties	11.48	11.13
EORTC QLQ-PR25	Urinary symptoms	19.76	19.47
	Urinary bother	15.57	14.79
	Bowel symptoms	7.29	7.10
	Treatment symptoms	10.62	10.17
	Sexual activity	67.80	68.61
	Sexual functioning	48.40	48.08
DASS-21	Depression	16.5%	16.3%
	Anxiety	16.4%	16.1%
	Distress	10.6%	10.4%

Depression, anxiety and distress were defined as men scoring ≥10, ≥8 and ≥15, on the respective subscales.21
*Using survey methods, weights were computed based on time since diagnosis, age at diagnosis and jurisdiction.
DASS, 21-question Depression, Anxiety and Stress (Di)Stress Scale; GHS, Global Health Status; NI, Northern Ireland; PiCTure, Prostate Cancer Treatment, your experience; RoI, Republic of Ireland.